Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | LTA4H | P09960 | 2/20 | 0.42 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1568390 | 0.85 | LMNA (0.57) | LMNAMAPTSMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL13533398 | 0.85 | LMNA (0.56) | LMNAMAPTSMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL13676827 | 0.85 | LMNA (0.56) | LMNAMAPTSMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL12340 | 0.85 | LMNA (0.56) | LMNAMAPTSMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL4461156 | 0.81 | LMNA (0.54) | LMNAMAPTSMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL10832911 | 0.81 | LMNA (0.57) | LMNAMAPTSMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL1567220 | 0.80 | LMNA (0.59) | LMNAMAPTSMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL12092432 | 0.79 | LMNA (0.51) | LMNAMAPTSMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL14105818 | 0.79 | LMNA (0.55) | LMNAMAPTSMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL13210307 | 0.79 | LMNA (0.55) | LMNAMAPTSMN1; SMN2NPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105669558-A | Benzyl-1H-pyrazole and benzyl-1H-pyrazole derivatives, and preparation method and application thereof | 四川大学 | 2016-06-15 | — | — | CN | disclosed |
| EP-1078928-B1 | Pyridine derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2004-05-12 | — | — | EP | disclosed |
| US-6486171-B2 | USEFUL IN THE TREATMENT OF SOME CENTRAL NERVOUS SYSTEM DISORDERS INCLUDING AS AN ANTIDEPRESSANT; 4-(1-(2-NAPHTHYL)ETHYL)-4- PIPERIDINYL)THIENO(3,2-C)PYRIDINE, FOR EXAMPLE | LES LABORATOIRES SERVIER (FR) | 2002-11-26 | — | — | US | disclosed |
| US-20020161228-A1 | Piperidine compounds | ADIR ET COMPAGNIE | 2002-10-31 | — | — | US | disclosed |
| US-6399616-B1 | 4-(4-(2-(5-(1,2,4-TRIAZOL-1-YLMETHYL)-1H-INDOL-3-YL)ETHYL)-1 -PIPERAZINYL)FURO(3,2-C)PYRIDINE; COMBINED SEROTONIN REUPTAKE INHIBITOR AND PARTIAL AGONIST OF 5-HT RECEPTORS; REDUCED LATENCY; DEPRESSION | LES LABORATOIRES SERVIER (FR) | 2002-06-04 | — | — | US | disclosed |
| EP-1078928-A1 | Pyridine derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161228-A1 | Piperidine compounds | OTC, NPPA, AQP4 | LMNA 1609/4885MAPT 574/4885SMN1; SMN2 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.